Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

Michael Friis

Head of Equities

Michael Friis portrait

Coverage

HydractAudientesRealfictionShape RoboticsScape TechnologiesGreenMobilityCurasightOrderYOYOPenneoPhotocatOdicoAgillicBawat Water TechnologiesImperoMapsPeopleNNITNordic SolarScandinavian Medical SolutionsWindowMaster InternationalGomSpace GroupCABA CapitalAscelia PharmaEmbla MedicalBioPortoGubraExpreS2ion Biotech Holding

Latest content

ShowingAll content types

BioPorto (Investment Case): Executing on the Forward strategy with adult pre-submission filed in Q1 2026

Research 01.04.2026 klo 17.37 by Philip Coombes, Michael Friis
BioPorto

WindowMaster (Investment case): High earnings growth set to return in 2026

Research 31.03.2026 klo 09.30 by Michael Friis, Victor Skriver
WindowMaster International

GreenMobility (Investment case): Proven profitability, levers for the next growth phase identified

Research 26.03.2026 klo 14.45 by Michael Friis, Victor Skriver
GreenMobility

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account

GreenMobility: Recording of 2025 annual report presentation

Analyst Comment 25.03.2026 klo 16.01 by Michael Friis
GreenMobility

ExpreS2ion: ES2B-C001 clears another hurdle: consistent immune responses and green light to escalate

Analyst Comment 25.03.2026 klo 12.17 by Michael Friis
ExpreS2ion Biotech Holding

Wirtek (Investment case): Well-positioned to increase profitability

Research 20.03.2026 klo 15.30 by Michael Friis, Victor Skriver
Wirtek

Wirtek: Recording of FY 2025 results presentation

Analyst Comment 19.03.2026 klo 16.57 by Michael Friis
Wirtek

Donkey Republic: Presentation of FY 2025 annual report (Recording)

Analyst Comment 19.03.2026 klo 15.05 by Michael Friis
Donkey Republic

GreenMobility: Strengthening the foundation for 2028 targets with record results and new fleet

Analyst Comment 19.03.2026 klo 11.29 by Michael Friis
GreenMobility

Wirtek: Q4 results and 2026 guidance align well with the ambitions to raise profitability

Analyst Comment 17.03.2026 klo 11.30 by Michael Friis
Wirtek
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.